

**REMARKS/ARGUMENTS**

The Examiner has determined that applicants' elected species is free of prior art. However, claim 1 as originally filed does read on the art, and is specifically anticipated by Guegan et al. when R<sub>6</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl.

Accordingly, applicants, through their attorney have amended their claims to exclude compounds of formula I wherein R<sub>6</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl.

The Examiner has indicated that claims 2 – 4 and 6-14 are withdrawn as not reading on the elected species. Reconsideration of this position is respectfully requested. The elected species, compound 14, is clearly covered by claim 2 ((Xaa<sup>1</sup> is Leu), claims 3 and 4 (Xaa<sup>2</sup> is Val) and claim 6 (formula IA). Claims 7 through 14 are all dependent from these claims, which cover the elected species.

Finally, upon entry of the instant amendment, claims 10 and 11 will be amended to include a generic description of the product sold under the trademark Colostrinin. The Examiner had indicated that use of a trademark on the claims does not comply with Section 112.

Application No. 10/840,037  
Amdt dated January 9, 2006  
Reply to Office action of August 23, 2005

In view of the foregoing, it is respectfully submitted that the subject application is in condition for allowance and such favorable action at an early date is earnestly solicited.

Respectfully submitted,




Mary-Ellen M. Devlin  
Attorney for Applicant(s)  
Reg. No. 27,928

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-4866  
Dated: January 9, 2006

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on January 9, 2006



By: Mary-Ellen M. Devlin  
Reg. No. 27,928